Tectonic Therapeutic Inc TECX
NASDAQ · United States · Commercial Services
$22.67-0.62 (-2.66%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investigational New Drug (IND) application for the TX2100 Phase 1b clinical trial in HHT patients in the U.S.TX2100 Phase 1a clinical trial topline results demonstrated single ascending doses of TX2100 were generally safe and well-tolerated in healthy adult volunteersCompany plans to initiate an open-label TX2100 Phase 1b clinical trial in patients with hematologic-support dependent HHT by year-end 2026, and initiate a
On August 6, Tectonic Therapeutic (NASDAQ:TECX) reported second quarter results built around two clinical wins rather than sales figures, since this is a clinical stage biotech company with no products on the market yet. The headline news is that both of its lead programs hit their scheduled marks this year, and the company says it […]
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.